Annual report pursuant to Section 13 and 15(d)

Revenue Recognition (Tables)

v3.24.0.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue by Service Line
Revenue by Service Line
Years Ended December 31,
(in thousands) 2023 2022
Biologics and drug delivery
Disposable products $ 2,154  $ 3,690 
Services and license fees 11,448  5,430 
               Subtotal – Biologics and drug delivery revenue 13,602  9,120 
Functional neurosurgery navigation and therapy
Disposable products 7,589  7,587 
Services 931  1,537 
Subtotal – Functional neurosurgery navigation and therapy revenue
 8,520  9,124 
Capital equipment and software
Systems and software products 860  1,512 
Services 973  795 
                     Subtotal – Capital equipment and software revenue 1,833  2,307 
Total revenue $ 23,955  $ 20,551 
Schedule of Other Current Assets These costs were classified as other current assets and were recognized as expense in 2023.
December 31, 2023 December 31, 2022
(in thousands)
Accounts receivable, net $ 3,211  $ 2,665 
Other contract assets
Unbilled receivables $ 733  $ 43 
Deferred contract costs $ —  $ 327 
Schedule of Revenue Recognized by Contract Liability
December 31, 2023 December 31, 2022
(in thousands)
Deferred revenues $ 3,154  $ 1,457 
Refund Liability $ —  $ 500